In France, menopause arrives at 51 on average. The transition leading up to it, perimenopause, brings its own distinct territory: irregular cycles, skin changes, and according to Inserm, a period of heightened neuropsychic vulnerability, particularly for women with a history of anxiety or depression.
This is a demographic reality that most skincare offers in France still treat as a single, undifferentiated life stage. The gap between what women in this transition actually experience and what brands put on shelf is wider than the industry's current language suggests.
Two different problems, one shelf
Perimenopause and menopause are not the same skin story. Perimenopause tends to bring inflammation, breakouts, and pigmentation shifts, driven by hormonal fluctuation rather than decline. Menopause and post-menopause bring a different set of changes: loss of elasticity, wrinkles, and thinning associated with the drop in estrogen production.
Most product lines do not draw that line. They treat “menopause skincare” as a single category, built around the same anti-aging vocabulary used for general mature-skin products, regardless of which phase a woman is actually in.
Where the market already stands
A few brands active in France have staked out ground here. Lierac's Arkéskin line, launched in 1996, is widely credited as the first menopause-specific skincare range on the market, and remains the clearest reference point after three decades. Vichy's Neovadiol line is marketed explicitly around menopause and post-menopause care. L'Oréal's Age Perfect line targets mature skin more broadly, without the same hormonal framing.
These brands proved the category has commercial legitimacy in France. The precision problem Kline identifies sits at the category level, not attached to any single brand audit: broad “menopause” and “anti-aging” language still dominates positioning across the segment, with little visible separation between perimenopause and menopause needs, and limited visible movement on inclusivity.
The gap that is still unclaimed
Three problems sit unaddressed in the current market. The first is language: skincare aimed at this life stage still leans heavily on “anti-aging” framing, a vocabulary that describes the visible endpoint of menopause but says nothing about the inflammatory, hormonally driven symptoms of perimenopause that come first.
The second is representation. Campaigns and product development in this category remain narrow in who they picture and consult, at a moment when demand for visibility is rising alongside education about hormonal skin health.
The third is inclusivity in a more specific sense: solutions built for melanin-rich skin going through menopause, across different climates and skin practices, remain limited. Given how large the menopausal population in France actually is, that is a significant share of existing demand left unaddressed, not a peripheral concern.
What this means for a brand entering France
A foreign brand looking at the French market has an opening here that does not require inventing a new category. It requires precision inside an existing one: separating perimenopause claims from menopause claims, rather than folding both into a single “anti-aging for mature skin” narrative.
It also means formulation and marketing that acknowledge hormonal skin changes as a mechanism, not just an age bracket, and representation that reflects the diversity of women actually going through this transition, rather than a narrow visual standard.
None of this requires competing head-on with Lierac's three decades of category ownership or L'Oréal's distribution reach. The space those brands have left open is specific enough to build a position around without confronting them directly.
Where to start
The brands that will win this segment in France will be the ones who can explain, precisely, which phase of the transition their product addresses, and to whom, rather than the ones shouting “menopause” the loudest.
If your brand is evaluating a France entry built around hormone-aware skincare, that precision is the first thing worth testing before anything else.
Sources
- Kline & Company, presentation at in-cosmetics Global, Paris, April 2026
- Inserm, Ménopause